Several germline mutations and variants of FA pathway genes have been reported as risk factors in cancer in non-FA patients/individuals; namely, mutations in BRCA1 (FANCS), PALB2 (FANCN), and BRCA2 (FANCD1) have been shown to lead to increased risk of breast and ovarian cancers, as well as prostate cancer (18–20). This evidence concerns the gene BRCA1 and Familial prostate cancer.